Equitor

Quick links to important sections

Equitor

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Equitor

Property Description
Active Ingredient Conjugated Estrogens (CEs)
Form Tablet (Oral), Cream, Powder (for Injection)
Pharmacological Class Estrogens, Hormonal Agent
General Purpose Hormone Replacement and Systemic Regulation
Origin Natural sources (Equine) or Synthetic Replications

Equitor: Identity and Classification as a Hormonal Agent

Equitor is a prescription medication characterized as a hormonal agent whose active substance is the distinct pharmaceutical preparation known as Conjugated Estrogens (CEs). This medication is specifically classified as an estrogen receptor agonist and belongs to the general pharmacological class of Estrogens. Its systemic function is rooted in Hormone Replacement Therapy (HRT), a type of intervention clinically recognized for addressing conditions associated with hormone depletion. The defining characteristic of Conjugated Estrogens is that it is a complex, standardized blend of multiple steroidal compounds, which sets it apart from treatments using a single, isolated estrogen.

Composition, Origin, and Pharmaceutical Form of Conjugated Estrogens

The active ingredient is a noncrystalline, water-soluble mixture of female sex hormones, primarily composed of their sodium sulfate conjugates. The key chemical substances are Sodium estrone sulfate and Sodium equilin sulfate, which are central to the blend’s activity. While historically sourced from natural sources (purified from the urine of pregnant mares, hence Conjugated Equine Estrogens), the active substance is now also available through precise synthetic replications that chemically mimic the natural mixture. Equitor is commonly manufactured for oral use as a tablet but is also available in preparations suitable for intramuscular, intravenous, or intravaginal administration. The unique complexity of the CEs mixture contributes to a distinctive pharmacological profile compared to monotherapy estrogens.

What is the General Purpose of Taking an Estrogen Replacement?

The overall purpose of this estrogen replacement medication is to support the stability of physiological functions that depend on adequate estrogen signaling. The core mechanism principle involves the active compounds binding to and stimulating estrogen receptors in various tissues throughout the body. By effectively establishing a new hormonal baseline, this drug performs Hormonal Replacement, which is typically employed to mitigate the general systemic discomfort and changes associated with conditions of estrogen depletion.

Regulatory References

  1. NIH/PubMed Review

What side effects are possible with Equitor?

Possible Side Effects and Safety Information

The safety profile for Conjugated Estrogens (Equitor) is structured by regulatory authorities to classify potential reactions and associated systemic risks. Adverse reactions are grouped by the physiological system affected and by their documented frequency.

Adverse Reactions by Classification

Classification Examples of Reactions Affected System-Organ Classes
Common Headache, Nausea, Breast pain or tenderness Nervous System, Gastrointestinal, Reproductive System
Uncommon/Rare Vomiting, Dizziness, Weight changes, Venous Thromboembolism, Cholestatic jaundice Hepatobiliary Disorders, Vascular Disorders

The official labeling notes several systems where effects may occur, including Gastrointestinal Disorders, Reproductive System and Breast Disorders, Nervous System Disorders, Skin and Subcutaneous Tissue Disorders, and Vascular Disorders.

Serious Adverse Reactions and Safety Constraints

Official regulatory information highlights the risk of several serious adverse reactions. These include the potential for venous thromboembolism (such as Deep Vein Thrombosis and Pulmonary Embolism), stroke, myocardial infarction, and certain malignancies (e.g., endometrial carcinoma, particularly with unopposed estrogen use, and breast cancer). The risk of these serious events is documented as increasing with the duration of use.

Specific safety considerations exist for certain populations. The official Prescribing Information notes an increased risk of probable dementia in women 65 years of age and older. The medication is restricted (contraindicated) for use in individuals with active or recent thromboembolic disease, known liver dysfunction, or a history of estrogen-dependent neoplasia.

Overdose and Emergency Response

️ Equitor Overdose and When to Seek Help

The official regulatory documentation for Conjugated Estrogens (Equitor) defines the overdose profile based on expected, typically non-life-threatening, clinical manifestations and mandates immediate professional guidance. There are no severe or life-threatening outcomes explicitly documented in the official overdose sections.

Documented Manifestations

Overdosage is formally associated with a distinct symptomatic cluster. Gastrointestinal effects commonly listed include nausea, vomiting, abdominal pain, and bloating. Other documented signs are local effects such as breast discomfort or tenderness, and general effects including drowsiness or fatigue. A significant genitourinary finding of vaginal bleeding or withdrawal bleeding is also listed, which may be followed by a period of amenorrhea of variable length. Regulatory documents note that these symptoms of overdosage may occur in children.

Mandated Emergency Response

In the event of a suspected overdose, regulatory guidance mandates immediately contacting a healthcare professional, a hospital emergency department, or a regional poison control center. The official prescribing information states that no specific antidote is known for this compound. Consequently, the treatment protocol is restricted to symptomatic and supportive care, focusing on addressing the documented manifestations until the effects naturally resolve.

Therapeutic Uses of Equitor

Equitor is generally applied across domains where additional symptomatic support is needed due to states of estrogen deficiency. It may assist with managing symptoms that create noticeable physiological strain. The medication is indicated for a range of conditions relevant to estrogen depletion.

The primary use of Equitor involves easing symptoms that are associated with moderate to severe vasomotor symptoms (hot flashes and night sweats), treatment of vulvar and vaginal atrophy (including dryness and dyspareunia), and supportive therapy for hypoestrogenism resulting from conditions like female hypogonadism or surgical castration. It is also considered relevant for preventing postmenopausal osteoporosis in high-risk women, and is applied in specific palliative contexts.

The medication plays a role in managing symptoms that interfere with daily comfort, such as persistent hot flashes and localized tissue irritation. “It is applied in addressing conditions where symptoms may intensify temporarily, providing support that helps ease the overall symptom burden.”

Quick Fact: Symptomatic Support for Vasomotor Symptoms The treatment is used for managing symptoms related to systemic imbalance, which helps maintain a sense of stability when symptoms are more noticeable and supports general well-being during symptomatic phases.

Eligibility and Restrictions for Use

Eligibility: Who Can and Cannot Use Equitor (Conjugated Estrogens)

Equitor is restricted by regulatory authorities to specific adult populations based on established risk profiles, pre-existing conditions, and physiological status. Eligibility is primarily for postmenopausal women seeking treatment for estrogen deficiency symptoms. Women who have an intact uterus are only eligible if the medication is taken with a concurrent progestin to mitigate the risk of endometrial hyperplasia.

Absolute Contraindications (Must Not Use)

Condition / History Restriction Type
Known or Suspected Pregnancy Absolute Contraindication
Active Liver Disease or Impairment Absolute Contraindication
History of Breast Cancer or Estrogen-Dependent Neoplasia Absolute Contraindication
Active or History of Thromboembolic Disease (DVT, PE, Stroke, MI) Absolute Contraindication

Restricted Populations

Population / Status Regulatory Classification
Pediatric Population Not Recommended (Safety and effectiveness not established)
Women 65 Years Caution (Increased risk of probable dementia reported)
Nursing Mothers Use is limited (May decrease breast milk quantity and quality)

What should I know about interactions with other medicines?

The regulatory profile for Equitor (Conjugated Estrogens) is defined by its interactions with substances that affect metabolic clearance and specific hormonal transport proteins. The most critical interactions are pharmacokinetic, driven by the hepatic CYP3A4 enzyme system.

Official Interaction Statements

  • Co-administration with potent CYP3A4 inducing agents is documented to cause a reduction in estrogen plasma concentrations (reduced AUC). Examples of inducers listed in regulatory sources include rifampicin, carbamazepine, and the herbal product St. John's Wort.
  • Conversely, concurrent use with CYP3A4 inhibiting agents may result in increased estrogen plasma concentrations (increased AUC). Inhibitors listed include ketoconazole, clarithromycin, and grapefruit juice.
  • Estrogens are formally documented to decrease the metabolic clearance of corticosteroids (e.g., prednisolone), which may increase the exposure and systemic effects of the co-administered agent.
  • Estrogens may cause an increase in Thyroid Binding Globulin (TBG). This effect requires consideration for potentially increased levothyroxine dose requirements to maintain adequate free hormone levels.

Connection to the overall interaction profile: The regulatory profile is primarily structured around established pharmacokinetic interactions resulting from interference with hepatic enzyme metabolism. Official documentation also notes pharmacodynamic interference related to the systemic effects of estrogens on transport proteins and the subsequent clearance of other hormonal agents. No mandatory timing-based separation rules are explicitly documented for the oral formulation, but caution regarding interactions is noted for individuals with impaired hepatic function.

Mechanism of Action

Targeted Modulation of T-Cell Signaling via CD6 Receptor Shedding

Equitor acts by binding specifically to the CD6 protein on the surface of T-cells, triggering the controlled release, or shedding, of the receptor from the cell membrane. This initial molecular action modifies a critical component of the cell's structure, thereby altering the T-cell's ability to receive activating signals that contribute to T-cell proliferation and function. This mechanism operates across domains involving receptor-mediated signaling and results in a targeted modification of immune cell behavior.


Modulating Signaling Cascades for Systemic Pathway Adjustment

By reducing the sensitivity and activity of key T-cells, Equitor affects an early stage of the signaling cascade. This systemic modification modulates the activity of immune processes and results in a reduction of signaling within the adaptive immune system. The resulting physiological effect is a shift in T-cell activity, influencing the balance of activity within the immune system's signaling pathways.

Dosage and Administration Information

How to Use Equitor: Official Administration Guidelines

Equitor (Conjugated Estrogens, CE) is administered through distinct routes, depending on the therapeutic application. The official routes of administration are Oral (tablet form), Intravaginal (cream), and Intravenous (IV) or Intramuscular (IM) injection.


Dosing and Administration Principles

Administration is governed by the principle of using the lowest effective dose for the shortest duration that is consistent with treatment goals. The dosage is subject to periodic reevaluation and adjustment based on individual clinical response.

  • Oral Tablets: These are taken once daily and may be administered without regard to meals. Tablets must be swallowed whole and should not be divided, crushed, or dissolved.
  • Dosing Cycles: Oral use is typically scheduled as either a continuous regimen (daily without interruption) or a cyclical pattern (e.g., 25 days of treatment followed by 5 days off). Palliative regimens, such as for breast cancer, require administration three times daily.
  • Missed Dose: If an oral dose is forgotten, it should be taken as soon as remembered. If multiple doses are missed, only the most recent missed dose should be taken, and doses should not be doubled.

Specialized Administration

For intravenous or intramuscular use, the 25 mg powder is first reconstituted with 5 mL of Sterile Water for Injection, USP, and the injection is administered slowly. Furthermore, a progestin must be considered for women with an intact uterus as part of the standard therapeutic protocol for the oral form.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Equitor

This section describes the types of clinical research and studies that was evaluated for Equitor, focusing on the evidence regulators have relied upon. The information here outlines what researchers explored and what their findings indicate, without offering any clinical guidance or recommendations.


Research Evidence for Moderate to Severe Hot Flashes (Vasomotor Symptoms)

The research base for severe vasomotor symptoms consists of large-scale Randomized Controlled Trials (RCTs) and systematic reviews. These studies was studied for how symptoms change over time. Researchers monitored the frequency and intensity of symptoms using patient diaries, focusing on outcomes related to systemic or functional imbalance. Populations studied were typically postmenopausal women experiencing symptoms. Findings describe patterns observed where the administration of the medicine was associated with recorded values in the patient-reported frequency and severity of hot flashes. Long-term outcomes are not fully established for women starting therapy immediately after menopause, and research provides limited specific insight into therapy maintenance.


Research Evidence for Vulvar and Vaginal Symptoms

The evidence includes a base of Randomized Controlled Trials that evaluated outcomes related to vulvar and vaginal symptoms. Studies explored outcomes linked to inflammatory or irritative states, monitoring subjective patient-reported outcomes and objective measures like tissue health indexes and pH levels. Short-term trials reported recorded values for these objective biomarkers. Studies reported how symptoms evolved, with patient self-assessment data describing temporary patterns in symptom metrics. The overall level of evidence is generally categorized as moderate. Data supporting the long-term durability of the observed objective tissue health indicators beyond the initial one-year follow-up period are not always consistently reported.


Research Evidence for Preventing Postmenopausal Bone Loss

Equitor was studied for the prevention of bone loss through long-term Randomized Controlled Trials (RCTs) and cohort studies. Key research examined changes in Bone Mineral Density (BMD) and the incidence of fragility fractures. Research highlights changes measured during the study period, where women who were observed in the trials reported patterns of higher measured BMD compared to control groups. Studies monitoring fracture incidence over several years reported patterns of specific fracture rates in the group receiving the medicine. The evidence must be considered alongside other observed long-term findings. Results apply only to the populations studied, and limited recent information is available for using lower doses specifically for bone loss prevention.

Frequently Asked Questions (FAQ)

Common questions about Equitor (FAQ)


Q: What is the main difference between Equitor and other common medicines for the same condition?

A: Official information describes the active ingredient, Conjugated Estrogens (CEs), as a complex mixture containing multiple naturally occurring estrogen compounds. This unique blend distinguishes it from treatments that use a single, isolated form of estrogen. This composition is its defining characteristic according to regulatory classifications.


Q: Does Equitor cause weight changes?

A: Weight changes, including both weight increase or decrease, have been reported in official safety documents. In some clinical studies, weight gain is specifically listed as a common adverse reaction. These details are available in the full regulatory safety information.


Q: Are there any common foods or drinks that should be avoided while using Equitor?

A: Official labeling explicitly identifies grapefruit juice as an inhibitor that may increase the level of the active substance in the body. Beyond grapefruit juice, regulatory documents do not commonly list other specific foods or drinks as interacting agents that significantly modify the drug’s effect.


Q: Is Equitor considered a long-term treatment option?

A: Official regulatory guidance recommends that estrogens should be used for the shortest duration that is consistent with treatment goals and individual risks. This principle guides how long treatment should continue rather than labeling it strictly as a short-term or long-term therapy.


Q: Does Equitor have a risk of dependence or withdrawal symptoms?

A: The drug's active substance, Conjugated Estrogens (CEs), is not classified as a controlled substance under the U.S. Controlled Substances Act. Furthermore, official safety documents do not list dependence or withdrawal symptoms among the common or serious adverse reactions.


Q: Can Equitor affect blood test results?

A: Yes, regulatory information indicates that estrogens are documented to cause an increase in various plasma proteins. This includes Thyroid Binding Globulin (TBG), which can affect the results of certain laboratory tests related to hormones.


Q: Does taking Equitor make you tired or sleepy?

A: Official safety documents list Asthenia (a condition of abnormal weakness) and unusual tiredness or weakness as less common adverse reactions. These reported effects may sometimes be perceived as changes in energy. Drowsiness itself is not commonly listed.


Q: Can Equitor affect my mood or emotional state?

A: Official labeling lists Emotional liabilities (such as mood instability) and Depression as common adverse reactions reported in clinical trials. Other issues like anxiety or mood disturbances have also been reported in safety data.


Q: What are the official sources that provide information about Equitor?

A: The most comprehensive official sources for factual drug information are provided by government agencies. These include the FDA Prescribing Information and DailyMed in the United States, and the Summary of Product Characteristics (SmPC) from the European Medicines Agency (EMA), along with similar documents from other national regulatory bodies.


Q: Is Equitor known to cause any skin reactions or rashes?

A: Official safety data lists Pruritus (itching) as a common reaction that may occur. Rash is also noted in official documents as a reaction that has been reported, often during postmarketing surveillance.


Q: Is there any research on the long-term safety of Equitor?

A: Yes, official labeling explicitly references the findings of large-scale, long-term studies, such as the Women’s Health Initiative (WHI) studies. The results of these studies are used by regulators to evaluate and define the risks associated with extended use.


Q: Is there a maximum time someone can stay on Equitor?

A: Official guidance recommends that estrogens should be used for the shortest duration consistent with treatment goals. While this encourages minimizing the duration of use, there is typically no specific maximum time limit or hard cap stated directly on the regulatory label.


Q: Can Equitor affect my vision?

A: Official warnings note that patients should check with a healthcare provider immediately if a sudden loss of vision or any change in vision occurs, or if symptoms such as double vision occur. These warnings are included in the precautions section of the official prescribing information.


Q: What is the intended outcome of treatment with Equitor?

A: The intended outcomes, as described in the official Indications for Use, include the relief of moderate to severe symptoms associated with menopause. This includes symptoms such as frequent hot flashes and changes related to vulvar/vaginal atrophy.


Q: Does Equitor cause stomach upset?

A: Official safety data lists several common gastrointestinal adverse reactions. These reactions include Nausea, Diarrhea, Constipation, Dyspepsia (indigestion), Eructation (belching), and Flatulence (gas).


Q: Is Equitor a daily medicine or taken as needed?

A: Oral administration is generally scheduled as a regimen that involves taking the medicine at set times. This is typically a continuous regimen (daily without interruption) or a cyclical pattern (e.g., 25 days on, 5 days off), depending on the specific condition being addressed.


Q: Is it normal to feel a change in energy levels when starting Equitor?

A: Official safety documents list Asthenia (lack of strength) and Unusual tiredness or weakness as less common adverse reactions. These effects are documented and may be perceived as a change in energy when beginning treatment.


Q: What if Equitor doesn't seem to be working for me?

A: Official regulatory documents state that the treatment requires periodic reevaluation by a healthcare professional based on the individual’s clinical response. This ensures the lowest effective dose is being used.


Q: Is it safe to use Equitor if I have kidney issues?

A: Official prescribing information notes that the components of the medicine are metabolized by the liver and eliminated by the kidney. Regulators advise Use with caution for individuals with pre-existing renal (kidney) impairment.


Q: What kind of monitoring is typically recommended while using Equitor?

A: Official precautions state that a patient's progress should be checked at regular visits. Monitoring may include procedures such as a pelvic exam, breast exam, and a mammogram to check for potential unwanted effects of the treatment.


Q: Are headaches a common side effect of Equitor?

A: Yes, official safety documents list Headache as a Common adverse reaction. It is one of the more frequently reported effects noted across clinical studies.


Q: Can I drink alcohol moderately while taking Equitor?

A: Official labeling explicitly lists grapefruit juice as an interacting inhibitor but does not commonly list alcohol as an interacting agent that modifies the drug's effect.

How should Equitor be stored and disposed of?

Equitor (lisinopril) tablets must be stored according to specific regulatory conditions to maintain stability and prevent degradation.

Storage Condition Requirements

Requirement Official Instruction
Temperature Store at Controlled Room Temperature (20 C to 25 C / 68 F to 77 F).
Protection Protect from moisture, freezing, and excessive heat.
Container Keep in the original container, tightly closed.
Child Safety Keep out of the reach of children.

Disposal Instructions

Official labeling directs that outdated or unused medication must not be kept. Patients should consult a pharmacist or healthcare professional for instructions on how to dispose of the product. Disposal must be conducted in accordance with local requirements and should not involve flushing the tablets down the toilet or throwing them into household waste unless specifically authorized.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Equitor found in:

A-Z Index: